Chronic Lymphocytic Leukemia Drugs Market by Drug Class (Brand) – Chemotherapy (Bendamustine); Kinase Inhibitors – Ibrutinib (Imbruvica), Idelalisib (Zydelig); Monoclonal Antibodies – Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Rituximab (Rituxan) and Forecast 2017-2021

Chronic Lymphocytic Leukemia Drugs Market by Drug Class (Brand) – Chemotherapy (Bendamustine); Kinase Inhibitors – Ibrutinib (Imbruvica), Idelalisib (Zydelig); Monoclonal Antibodies – Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Rituximab (Rituxan) and Forecast 2017-2021

Chronic lymphocytic leukemia (CLL) is one of the most common forms of leukemia. American Cancer Society estimates about 20,110 new cases of chronic lymphocytic leukemia in the United States for 2017. CLL accounts for about one-quarter of the new cases of leukemia. The main treatments used includes chemotherapy, monoclonal antibodies, targeted therapy, supportive care, and stem cell transplant. There are 2 general categories of systemic therapy used for CLL: chemotherapy and targeted therapy. The types of chemotherapy drugs include Bendamustine (Treanda), Fludarabine (Fludara), Pentostatin (Nipent), Cladribine (Leustatin), Chlorambucil (Leukeran), and Cyclophosphamide (Neosar). Targeted therapy treatment include monoclonal antibodies like Rituximab (Rituxan), Ofatumumab (Arzerra), Obinituzumab (Gazyva), and kinase inhibitors such as Ibrutinib (Imbruvica), Idelalisib (Zydelig), and Venetoclax (Venclexta). The following combinations may be used for CLL: Rituximab (Rituxan) and fludarabine (FR), Cyclophosphamide and fludarabine (FC), Cyclophosphamide, fludarabine and rituximab (FCR), Pentostatin, cyclophosphamide, and rituximab (PCR), Bendamustine (Treanda) and rituximab (BR), Idelalisib and rituximab for patients with recurrent CLL, Obinituzumab and chlorambucil for older patients.

The global chronic lymphocytic leukemia drugs market segmentation is based on drug class (brand) –  chemotherapy (Bendamustine); kinase inhibitors – Ibrutinib (Imbruvica), Idelalisib (Zydelig); monoclonal antibodies – Obinutuzumab (Gazyva), Ofatumumab (Arzerra), Rituximab (Rituxan).

The global chronic lymphocytic leukemia drugs market research report provides market size (Revenue USD Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global chronic lymphocytic leukemia drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global chronic lymphocytic leukemia drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries.  The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major players operating in the global chronic lymphocytic leukemia drugs market and profiled in this report include AbbVie, Angstrom Pharmaceuticals, AstraZeneca, Celgene, Cyclacel, Gilead Sciences, Infinity, MedImmune, MorphoSys, Novartis, NOXXON Pharma, Roche, Teva Pharmaceutical Industries Ltd., and TG Therapeutics.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Chronic Lymphocytic Leukemia (CLL) Drugs Market

1. Drug Class (Brand)
1.1. Chemotherapy
1.1.1. Bendamustine
1.2. Kinase Inhibitors
1.2.1. Ibrutinib (Imbruvica)
1.2.2. Idelalisib (Zydelig)
1.3. Monoclonal Antibodies
1.3.1. Obinutuzumab (Gazyva)
1.3.2. Ofatumumab (Arzerra)
1.3.3. Rituximab (Rituxan)

2. Geography
2.1. North America (U.S., Canada)
2.2. Latin America (Brazil, Mexico, Rest of LA)
2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
2.4. Asia Pacific (Japan, China, India, Rest of APAC)
2.5. Rest of the World

3. Company Profiles
3.1. AbbVie
3.2. Angstrom Pharmaceuticals
3.3. AstraZeneca
3.4. Celgene
3.5. Cyclacel
3.6. Gilead Sciences
3.7. Infinity
3.8. MedImmune
3.9. MorphoSys
3.10. Novartis
3.11. NOXXON Pharma
3.12. Roche
3.13. Teva Pharmaceutical Industries Ltd.
3.14. TG Therapeutics

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*